The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Jan. 14, 2025 — There may be a link between hearing impairment and an increased risk of developing Parkinson's according to new research. This is one of the first studies to examine whether ...